Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
480 participants
OBSERVATIONAL
2015-04-18
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group with PE
The criteria for confirmation of PE are:
PE on spiral computed tomography (CT) proximal deep vein thrombosis on ultrasound (US) thromboembolic events objectively confirmed during the follow up
No interventions assigned to this group
Group without PE
The criteria for exclusion of PE are:
low or moderate clinical probability and D-dimer ELISA \<0.50 µg/mL or \<10xage in patients older than 50 years and negative follow up low and moderate clinical probability and negative CT and negative follow up high clinical probability and negative CT, US and follow up.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With suspected PE defined as new onset of or worsening of shortness of breath or chest pain
Exclusion Criteria
* Life expectancy less than 3 months
* First symptoms 15 day or more before inclusion
* Inability to the follow-up visits
* Therapeutic anticoagulation for any indication
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Institute of Heart, Lung and Blood Vessel Diseases
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jie Du, PhD
Role: STUDY_DIRECTOR
Beijing Anzhen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yulin Li, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PE2019
Identifier Type: -
Identifier Source: org_study_id